Article Sidebar

Download
PDF (Français (Canada))
Statistic
Read Counter : 0 Download : 0

Downloads

Download data is not yet available.

Main Article Content

Abstract

RÉSUMÉ
Introduction. L’hyperuricémie asymptomatique est fréquente au cours des maladies rénales et associée à leur incidence et à leur progression, mais sa prise en charge demeure controversée. À Madagascar, les données sur sa prévalence et ses facteurs associés chez les patients atteints de maladie rénale sont limitées. Cette étude a déterminé la prévalence de l’hyperuricémie asymptomatique et ses facteurs associés chez des patients hospitalisés pour maladie rénale à Antananarivo. Méthodes. Étude rétrospective transversale descriptive menée dans trois centres hospitaliers d’Antananarivo de janvier 2023 à janvier 2024. Nous avons inclus tous les patients hospitalisés pour maladie rénale ayant bénéficié d’un dosage de l’uricémie. L’hyperuricémie asymptomatique était définie par une uricémie > 420 µmol/L chez l’homme et > 360 µmol/L chez la femme, sans signes ni antécédents de goutte. Résultats. Sur 1 892 patients hospitalisés, 197 ont été retenus. La prévalence de l’hyperuricémie asymptomatique était de 75,1 % (148/197). L’âge moyen était de 56,1 ± 15,9 ans, avec une prédominance masculine (sex‑ratio 1,46). Les facteurs significativement associés étaient le sexe masculin (OR = 2,19), l’hypertension artérielle (OR = 2,34), le tabagisme (OR = 2,35) et l’utilisation de diurétiques (OR = 2,09). L’hyperuricémie était également associée à l’insuffisance rénale aiguë sur insuffisance rénale chronique (OR = 4,09), aux formes globales d’insuffisance rénale aiguë (OR = 4,09) et chronique (OR = 2,03), ainsi qu’aux stades G2 à G5 de la maladie rénale chronique (OR croissant de 6,9 à 13,5). Conclusion. L’hyperuricémie asymptomatique est très fréquente chez les patients atteints de maladie rénale à Antananarivo et associée à des facteurs cardiovasculaires et à la sévérité de l’atteinte rénale. Des études prospectives sont nécessaires pour guider la prise en charge.
 
ABSTRACT
Introduction. Asymptomatic hyperuricemia is common in kidney disease and associated with its incidence and progression, but its management remains controversial. In Madagascar, data on its prevalence and associated factors in patients with kidney disease are limited. This study determined the prevalence of asymptomatic hyperuricemia and its associated factors in patients hospitalized for kidney disease in Antananarivo. Methods. We conducted a retrospective descriptive cross‑sectional study in three Antananarivo hospitals from January 2023 to January 2024. We included all patients hospitalized for kidney disease who had a serum uric acid measurement. Asymptomatic hyperuricemia was defined as uric acid >420 µmol/L in men and >360 µmol/L in women, without signs or history of gout. Results. Among 1,892 hospitalized patients, 197 were included. The prevalence of asymptomatic hyperuricemia was 75.1% (148/197). Mean age was 56.1±15.9 years, with male predominance (sex ratio 1.46). Factors significantly associated were male sex (OR=2.19), hypertension (OR=2.34), smoking (OR=2.35), and diuretic use (OR=2.09). Hyperuricemia was also associated with acute‑on‑chronic kidney injury (OR=4.09), overall acute kidney injury (OR=4.09), overall chronic kidney disease (OR=2.03), and CKD stages G2 to G5 (OR increasing from 6.9 to 13.5). Conclusion. Asymptomatic hyperuricemia is very frequent in patients with kidney disease in Antananarivo and is associated with cardiovascular factors and severity of renal impairment. Prospective studies are needed to guide management.

Keywords

atteinte rénale aiguë, hyperuricémie asymptomatique, insuffisance rénale chronique, maladie rénale acute kidney injury, asymptomatic hyperuricemia, chronic kidney disease, kidney disease.

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite
Rakotonirainy Oliva Henintsoa, Andrianiaina Mamonjisoa Olivier, Rabemananjara Mialisoa Elianne, Radinasoa Rajo Paidia, Rapelanoro Rabenaja Fahafahntsoa, & Vololontiana Hanta Marie Danielle. (2026). Asymptomatic Hyperuricemia During Renal Diseases in Three Hospital Centers in Antananarivo, Madagascar : Hyperuricémie Asymptomatique au Cours des Maladies Rénales dans Trois Centres Hospitaliers d’Antananarivo Madagascar. HEALTH SCIENCES AND DISEASE, 27(6), 1–8. https://doi.org/10.5281/zenodo.20182159
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. Gustafsson D, Unwin R. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013;14:164. https://doi.org/10.1186/1471-2369-14-164
  2. 2. Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, et al. Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care Res (Hoboken). 2019;71:427‑34. https://doi.org/10.1002/acr.23607
  3. 3. Shaheen SA, Barrouq DM, Irshaidat T. An up-todate systematic review on real-world evidence for the management of asymptomatic hyperuricemia. The Journal of Medical Research. 2023;9:96‑103.
  4. 4. Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang D-H, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013;28:2221‑8. https://doi.org/10.1093/ndt/gft029
  5. 5. Hisatome I, Li P, Miake J, Taufiq F, Mahati E, Maharani N, et al. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia. Circ J. 2021;85:130‑8. https://doi.org/10.1253/circj.CJ-20-0406
  6. 6. Gaubert M, Bardin T, Cohen-Solal A, Diévart F, Fauvel J-P, Guieu R, et al. Hyperuricemia and Hypertension, Coronary Artery Disease, Kidney Disease: From Concept to Practice. Int J Mol Sci. 2020;21:4066. https://doi.org/10.3390/ijms21114066
  7. 7. Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. Biomed Res Int. 2015;2015:762820. https://doi.org/10.1155/2015/762820
  8. 8. Doualla M, Nkeck JR, Halle MP, Felicité K, Agouak AI, Essouma M, et al. Modifiable and Non-Modifiable Factors Associated with Hyperuricemia in Patients Receiving Chronic Hemodialysis in Douala (Cameroon). HEALTH RESEARCH IN AFRICA [Internet]. 2023 [cité 19 sept 2025];1. http://hsd-fmsb.org/index.php/HRA/article/view/4703. Consulté le 19 sept 2025
  9. 9. Adejumo OA, Okaka EI, Madumezia G, Okwuonu CG, Ojogwu LI. Assessment of some cardiovascular risk factors in predialysis chronic kidney disease patients in Southern Nigeria. Niger Med J. 2015;56:394‑9. https://doi.org/10.4103/0300-1652.171616
  10. 10. Yirdaw AK, Ayele YY, Alemu H, Tesfaye T, Hailu W, Getahun D. Prevalence and associated factors of hyperuricemia in chronic kidney disease: evidence from a single-center hospital-based study in Ethiopia, 2024. Sci Rep. 2025;15:38938. https://doi.org/10.1038/s41598-025-22831-4
  11. 11. Kumar A U A, Browne LD, Li X, Adeeb F, Perez-Ruiz F, Fraser AD, et al. Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: A cohort study. PLoS One. 2018;13:e0198197. https://doi.org/10.1371/journal.pone.0198197
  12. 12. Gonçalves DLN, Moreira TR, da Silva LS. A systematic review and meta-analysis of the association between uric acid levels and chronic kidney disease. Sci Rep. 2022;12:6251. https://doi.org/10.1038/s41598-022-10118-x
  13. 13. Kuwabara M, Bjornstad P, Hisatome I, Niwa K, Roncal-Jimenez CA, Andres-Hernando A, et al. Elevated Serum Uric Acid Level Predicts Rapid Decline in Kidney Function. Am J Nephrol. 2017;45:330‑7. https://doi.org/10.1159/000464260
  14. 14. Kang MW, Chin HJ, Joo K-W, Na KY, Kim S, Han SS. Hyperuricemia is associated with acute kidney injury and all-cause mortality in hospitalized patients. Nephrology (Carlton). 2019;24:718‑24. https://doi.org/10.1111/nep.13559
  15. 15. Xu X, Hu J, Song N, Chen R, Zhang T, Ding X. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrol. 2017;18:27. https://doi.org/10.1186/s12882-016-0433-1
  16. 16. Pascart T, Latourte A, Flipo R-M, Chalès G, Coblentz-Baumann L, Cohen-Solal A, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine. 2020;87:395‑404. https://doi.org/10.1016/j.jbspin.2020.05.002
  17. 17. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29‑42. https://doi.org/10.1136/annrheumdis-2016-209707
  18. 18. Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2017;56:1056‑9. https://doi.org/10.1093/rheumatology/kex150
  19. 19. Drapkina OM, Mazurov VI, Martynov MI, Nasonov EL, Saiganov SA, Lila AM, et al. Consensus statement on the management of patients with asymptomatic hyperuricemia in general medical practice. HERALD of North-Western State Medical University named after II Mechnikov. 2025;17:113‑32.
  20. 20. Rashid I, Katravath P, Tiwari P, D’Cruz S, Jaswal S, Sahu G. Hyperuricemiaa serious complication among patients with chronic kidney disease: a systematic review and meta-analysis. Exploration of medicine. Open Exploration; 2022;3:249‑59.
  21. 21. Hak AE, Curhan GC, Grodstein F, Choi HK. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69:1305‑9. https://doi.org/10.1136/ard.2009.109884
  22. 22. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease. Int J Mol Sci. 2021;22:9221. https://doi.org/10.3390/ijms22179221
  23. 23. Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811‑21. https://doi.org/10.1056/NEJMra0800885
  24. 24. de Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr. 2012;4:12. https://doi.org/10.1186/1758-5996-4-12
  25. 25. Moulin SR, Baldo MP, Souza JB, Luchi WM, Capingana DP, Magalhães P, et al. Distribution of Serum Uric Acid in Black Africans and Its Association With Cardiovascular Risk Factors. J Clin Hypertens (Greenwich). 2017;19:45‑50. https://doi.org/10.1111/jch.12863
  26. 26. Kuwabara M, Niwa K, Hisatome I, Nakagawa T, Roncal-Jimenez CA, Andres-Hernando A, et al. Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic Diseases: Five-Year Japanese Cohort Study. Hypertension. 2017;69:1036‑44. https://doi.org/10.1161/HYPERTENSIONAHA.116.08998
  27. 27. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63:102‑10. https://doi.org/10.1002/acr.20344
  28. 28. Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014;9:e114259. https://doi.org/10.1371/journal.pone.0114259
  29. 29. Li P, Li X, Li G, Wang B, Liu Y, Zhao Y, et al. The association between smoking and the occurrence of hyperuricemia: A retrospective cohort study. Tob Induc Dis. 2025;23. https://doi.org/10.18332/tid/204253
  30. 30. Chien K-L, Hsu H-C, Sung F-C, Su T-C, Chen M-F, Lee Y-T. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: The Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis. 2005;183:147‑55. https://doi.org/10.1016/j.atherosclerosis.2005.01.018
  31. 31. Alberg A. The influence of cigarette smoking on circulating concentrations of antioxidant micronutrients. Toxicology. 2002;180:121‑37. https://doi.org/10.1016/s0300-483x(02)00386-4
  32. 32. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442‑7. https://doi.org/10.1016/j.amjmed.2006.06.040
  33. 33. Kowalczyk J, Francuz P, Swoboda R, Lenarczyk R, Sredniawa B, Golda A, et al. Prognostic significance of hyperuricemia in patients with different types of renal dysfunction and acute myocardial infarction treated with percutaneous coronary intervention. Nephron Clin Pract. 2010;116:c114-122. https://doi.org/10.1159/000314660
  34. 34. Liu Y-H, Tan N, Liu Y, Ye P, He Y-T, Ran P, et al. [The relationship between hyperuricemia and contrast-induced nephropathy in patients with chronic kidney disease undergoing percutaneous coronary intervention]. Zhonghua Xin Xue Guan Bing Za Zhi. 2013;41:740‑3.
  35. 35. Barbieri L, Verdoia M, Schaffer A, Cassetti E, Marino P, Suryapranata H, et al. Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI. Nutr Metab Cardiovasc Dis. 2015;25:181‑6. https://doi.org/10.1016/j.numecd.2014.08.008
  36. 36. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol. 2009;20:223‑8. https://doi.org/10.1681/ASN.2007080837
  37. 37. N P, M J, Br H, J D, M T, S K. Modification of outcomes after acute kidney injury by the presence of CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation. Am J Kidney Dis; 2011;58. https://doi.org/10.1053/j.ajkd.2011.01.028
  38. 38. Oh TR, Choi HS, Kim CS, Bae EH, Ma SK, Sung S-A, et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep. 2019;9:6681. https://doi.org/10.1038/s41598-019-43241-3
  39. 39. Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:212. https://doi.org/10.1038/s41392-024-01916-y
  40. 40. Eleftheriadis T, Golphinopoulos S, Pissas G, Stefanidis I. Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial. J Adv Res. 2017;8:555‑60. https://doi.org/10.1016/j.jare.2017.05.001
  41. 41. Yang H, Ying J, Zu T, Meng X-M, Jin J. Insights into renal damage in hyperuricemia: Focus on renal protection (Review). Mol Med Rep. 2024;31:59. https://doi.org/10.3892/mmr.2024.13424
  42. 42. Doualla M, Halle MP, Moutchia J, Tegang S, Ashuntantang G. Determinants of hyperuricemia in non-dialysed chronic kidney disease patients in three hospitals in Cameroon. BMC Nephrol. 2018;19:169. https://doi.org/10.1186/s12882-018-0959-5
  43. 43. Zhou J, Zhang Y, Cheng L. Meta-analysis of the effect of losartan relative to other angiotensin receptor antagonists on serum uric acid level. Tropical Journal of Pharmaceutical Research. 2023;22:1999‑2008.
  44. 44. T H, K I, M H, E M, K Y, K S, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. American journal of hypertension. Am J Hypertens; 2008;21. https://doi.org/10.1038/ajh.2008.245
  45. 45. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72:744‑60. https://doi.org/10.1002/acr.24180
  46. 46. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16:58. https://doi.org/10.1186/s12882-015-0047-z
  47. 47. Su X, Xu B, Yan B, Qiao X, Wang L. Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis. PLoS One. 2017;12:e0187550. https://doi.org/10.1371/journal.pone.0187550
  48. 48. Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, et al. Effects of Allopurinol on the Progression of Chronic Kidney Disease. N Engl J Med. 2020;382:2504‑13. https://doi.org/10.1056/NEJMoa1915833
  49. 49. Afkarian M, Polsky S, Parsa A, Aronson R, Caramori ML, Cherney DZ, et al. Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data. Diabetes Care. 2019;42:1454‑63. https://doi.org/10.2337/dc19-0342

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.